News

New president fires against EU
Enlarge image

PoliticsEU

New president fires against EU

25.06.2013 - Sanofi’s CEO Christopher Viehbacher has been elected head of Europe’s pharma lobby organisation EFPIA. He started off with threatening EU politicians.

Christopher A. Viehbacher, Chief Executive Officer of Sanofi, was elected President of EFPIA, the European Federation of Pharmaceutical Industries and Associations, for a 2-year term. Viehbacher, holding both German and Canadian nationalities, took the chance after the election on June 24 to take up a stance on EU politics. The quarrel is about the European Medicine Agency’s (EMA) strategy to make drug development more transparent by disclosing data from clinical studies. The EMA hopes that the released data on already approved drugs could spur research in general. The industry, however, believes competitors from the biologics field may gain valuable information and thus feels bullied. Speaking of his very own Sanofi, Viehbacher argues in a Reuters release: „If I was to say where would I put the next euro of investment, I would say either the next euro of investment would go to the United States or to emerging markets.“ The data in question also includes information that may help competitors in the field, Viehbacher fears that other companies like GSK or Roche got less exercised on the issue. They plan to open the corresponding raw data files for qualified researchers.

Beyond that discussion, Viehbacher also identified other construction sites, The EFPIA head urged: „Given the chronic deficits of healthcare systems, we must work differently, build collaborative policies and combine our strengths at both national and European levels. As we want Healthcare to be a growth engine for Europe, our industry must focus on three priorities: patient access, science & innovation and competitiveness.” Viehbacher follows Andrew Witty from UK’s GlaxoSmithKline. Joining him at the head of the EFPIA board will be two newly elected Vice Presidents, Roch Doliveux, Chief Executive Officer of UCB, and Joseph Jimenez, Chief Executive Officer of Novartis.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-02/new-president-fires-against-eu.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.65 EUR6.00%
  • FORMYCON10.90 EUR4.51%
  • CYTOS0.29 CHF3.57%

FLOP

  • BIOTEST79.48 EUR-2.68%
  • ADDEX2.99 CHF-1.97%
  • EVOTEC3.23 EUR-1.22%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.16 EUR46.2%
  • FORMYCON10.90 EUR38.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.59 EUR-10.7%
  • ADDEX2.99 CHF-9.4%

TOP

  • SANTHERA92.95 CHF2525.7%
  • CO.DON2.65 EUR154.8%
  • BB BIOTECH183.40 EUR63.9%

FLOP

  • CYTOS0.29 CHF-91.3%
  • 4SC0.90 EUR-48.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 25.11.2014